Zepbound beats Wegovy for weight loss
Digest more
According to a study funded by Eli Lilly, the trial revealed that participants taking tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds, while those who took semaglutide, or Wegovy, lost about 33 pounds. The two weight-loss drugs are ...
The best metric is not weight, but a particularly toxic kind of fat.
A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes drugs from compounding pharmacies.
A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement levels. The company most associated with obesity treatments, Denmark-based Novo Nordisk (NYSE: NVO),
Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal regulators crack down on the